Eiger Biopharmaceuticals (NASDAQ:EIGR) Trading 5.8% Higher

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) shares traded up 5.8% during trading on Wednesday . The company traded as high as $12.50 and last traded at $12.00, 266,321 shares traded hands during trading. An increase of 58% from the average session volume of 168,141 shares. The stock had previously closed at $11.34.

Several equities research analysts have weighed in on the company. KeyCorp initiated coverage on Eiger Biopharmaceuticals in a report on Wednesday, June 26th. They issued an “overweight” rating and a $10.72 price objective for the company. ValuEngine raised Eiger Biopharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 2nd. Citigroup initiated coverage on Eiger Biopharmaceuticals in a report on Wednesday, June 26th. They set a “buy” rating and a $22.00 target price for the company. BidaskClub raised Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 30th. Finally, Zacks Investment Research upgraded shares of Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a report on Tuesday, August 13th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $28.34.

The business has a fifty day simple moving average of $10.59 and a two-hundred day simple moving average of $11.58. The company has a current ratio of 9.64, a quick ratio of 9.64 and a debt-to-equity ratio of 0.36. The stock has a market cap of $273.30 million, a PE ratio of -3.14 and a beta of 1.04.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.75) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.73) by ($0.02). On average, research analysts predict that Eiger Biopharmaceuticals Inc will post -2.51 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of EIGR. BlackRock Inc. raised its holdings in Eiger Biopharmaceuticals by 281.9% in the second quarter. BlackRock Inc. now owns 1,729,161 shares of the biotechnology company’s stock worth $18,330,000 after purchasing an additional 1,276,408 shares in the last quarter. Cormorant Asset Management LP purchased a new stake in shares of Eiger Biopharmaceuticals in the 2nd quarter worth about $12,190,000. Farallon Capital Management LLC bought a new position in shares of Eiger Biopharmaceuticals in the 2nd quarter worth about $10,600,000. Vanguard Group Inc. increased its stake in shares of Eiger Biopharmaceuticals by 39.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,070,914 shares of the biotechnology company’s stock worth $11,352,000 after acquiring an additional 300,279 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new stake in Eiger Biopharmaceuticals in the second quarter worth about $3,168,000. 84.67% of the stock is currently owned by institutional investors.

Eiger Biopharmaceuticals Company Profile (NASDAQ:EIGR)

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Featured Story: How to trade the most active stocks

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.